Eli Lilly's triple-agonist compound Retatrutide has produced the most significant weight reduction data of any investigational peptide to date. Here is what the Phase 3 trial data shows and why researchers are paying attention.
View the full PeptX research peptide catalogue, or browse Retatrutide, Tirzepatide, Semaglutide, BPC-157, TB-500 and GHK-Cu.